Resources

New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs

Autumn Budget, AI regulation and new transatlantic partnerships: how we’re driving scale and capital for UK biotechs.

Peptide drug discovery uses peptides to investigate biological targets and develop potential therapeutics. The blog covers their key advantages, applications in screening and SAR, major challenges such as stability and delivery, optimisation strategies, and how o2h Discovery supports peptide synthesis and drug discovery workflows.

The NML has published its Annual Review 2025, reflecting on a year of scientific achievement, collaboration and investment in the future of UK chemical and biological measurement science. The Review showcases how the NML’s trusted measurement expertise is enabling innovation to be translated into real-world impact, supporting UK growth and regional expertise, and strengthening public confidence in policy and government decisions. If you would like to discuss any of the work featured in this Review or explore future collaboration opportunities with the NML, please contact [email protected]

Join Winston Taylor and Raymond James on 23rd September 2026 in London, as we bring together leaders who've built, scaled, and exited growth-stage businesses. A sharp, practical discussion on the routes to growth, liquidity, and exit.

UK Life Sciences Innovation Signals Report (H1 2026) explores how effectively the UK is converting scientific innovation into commercial growth, healthcare adoption, and patient impact. The report assesses three critical areas: Capital, Capability, and Conversion, revealing that while investment remains strong (£2.83bn raised in H1 2026) and research capabilities continue to improve, the sector's biggest challenge is turning innovation into widespread adoption across healthcare systems and markets. Key findings show that funding is increasingly concentrated in a small number of high-conviction companies, regulatory and clinical trial processes are becoming more efficient, and NHS adoption of new innovations is improving but remains inconsistent. The report provides valuable insights for founders, CFOs, investors, and industry leaders looking to understand the trends, opportunities, and challenges shaping the future of UK life sciences.

Precision BioSearch partners with Cytospire Therapeutics to appoint Sumeet Ambarkhane as CMO

Pioneer Group and Oxford Properties have announced that Syncona Investment Management Ltd (SIML), a leading life science investment manager, is moving into Victoria House, a leading hub for life sciences in London.

IMU Biosciences has formed a strategic partnership with Eurofins Transplant Genomics, with an exclusive licensing agreement to give the company access to IMU’s proprietary HD Immunology platform for transplant-related clinical development programmes.

What do the six most dangerous hospital superbugs have in common, and what makes each one distinct? MORF-Bio's live webinar compares all six genomes to find out.

Brainomix, a leading medtech company specializing in AI-powered imaging tools for lung disease and stroke, and Endeavor BioMedicines, a clinical-stage biotechnology company, presented positive results from the Brainomix AI-driven quantitative analysis of HRCT imaging data in Endeavor's Phase 2a trial of taladegib in idiopathic pulmonary fibrosis (IPF) at the European Respiratory Society (ERS) Conference in Barcelona.

How recent British Business Bank commitments and BIA member milestones are keeping UK life sciences momentum strong

Stevenage Bioscience Catalyst Board appoints Andrew Waters as Chief Executive Officer

Tangram Therapeutics announces progression to patient cohorts in Phase 1/2 RESTORE-MASH trial of TGM-312 and appointment of Dr Sonya Montgomery as Chief Development Officer

Coulter Partners successfully led a search assignment for NRG Therapeutics Ltd. and is pleased to announce the placement of Claus Sundgreen, M.D. as Chief Medical Officer (CMO).

Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has been selected to present at a number of leading international conferences this September.

Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases.

Foventa has strengthened its management team with a new CMO Dr Zaiba Malik and CFO Julia Jones as the company prepares for a Series A funding round to take lead asset FOV407 into a Phase IIb trial.